{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-24-000010","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.277214+00:00","generated_at":"2026-06-03T08:57:56.733383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed","bullets":["GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.","Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.","Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.","Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.","Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-24-000010","json":"https://secwatch.observer/filing/0000882095-24-000010.json","markdown":"https://secwatch.observer/filing/0000882095-24-000010.md","text":"https://secwatch.observer/filing/0000882095-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/0000882095-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/gild-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:57:56.733383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a77676db7e123e135c2e5ab0f7de6ec41065605","claim":"GILEAD SCIENCES, INC. reported the quarter ended March 31, 2024 results: revenue $6.7 billion, EPS $(3.34).","evidence_excerpt":"providing updates on this and our broad Oncology portfolio throughout the rest of 2024.” First Quarter 2024 Financial Results • Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales. • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/0000882095-24-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.7 billion"},{"label":"EPS","value":"$(3.34)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}